Schering-Plough moves forward on Zegerid switch, responds to FDA complete response letter

SAN DIEGO There is still an opportunity for a second proton-pump inhibitor to join Novartis Consumer Healthcare’s Prevacid 24HR this fall.

Santarus on Tuesday announced that Schering-Plough HealthCare Products has submitted its response to the Food and Drug Administration’s complete response letter issued in January.

Schering-Plough had licensed the OTC switch rights from Santarus for Zegerid, an omeprazole/sodium bicarbonate combination product, in 2006.